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ABSTRACT
In the 1990s, the definition of asthma changed as we
realized that asthma is fundamentally an inflammatory
disorder. It was also shown in both adults and chil-
dren that treatment should be initiated with anti-
inflammatory medication (preferably inhaled steroids)
and delayed treatment may worsen lung function
outcome. There is increasing evidence that, in both
children and adults, early and effective therapy with
inhaled steroids results in long-term remission in the
majority of patients. In future, even intermittent asthma
symptoms will be treated with inhaled steroids. The first
signs of asthma should be treated effectively, even in
small babies. In children with atopic dermatitis, early
pharmacotherapy may prevent asthma and in children
with hay fever, specific immunotherapy may reduce the
asthma risk. Airway eosinophilia predisposes a patient
to asthma. The benefit of early intervention in patients
who show eosinophilic airway inflammation but have
normal or near normal lung function has been recently
demonstrated. It seems that we should treat ‘asthma
even before asthma’, if the disease is defined in terms
of lung function. Persistent asthma is difficult to
reverse, but early stages of asthma could be more
responsive to novel therapies, such as drugs modifying
the pro-inflammatory cytokines or monoclonal anti-
bodies against IgE. The emerging new methods to
assess airway inflammation will cast light on the origin
of asthma, as well as on the determinants of disease
persistence. Along with the development of practical
inflammatory markers, the doctor gets a clearer
picture of the disease. This means a better understand-
ing for the doctor and better tailored treatment for the
patient and this will further improve treatment results.
Key words: early asthma, eosinophilic inflammation,
inhaled corticosteroids.
INTRODUCTION
Our thinking has changed along with the appraisal of
bronchial asthma as an inflammatory disease. The mech-
anistic idea of asthma as an enhanced bronchospasm
has been replaced by a more holistic view regarding
asthma as a biologic continuum from mild episodes of
‘asthmatic’ inflammation to fatal attacks. Asthma is a
man-made definition and quite arbitrary. Lung function
tests (e.g. peak flow measurements) are useful in moni-
toring patients with moderate to severe persistent asthma,
but they give only indirect evidence of the airway pathol-
ogy and are insensitive to early signs of asthma.
Asthma, as defined by lung function terms, is a conse-
quence of airway inflammation, in which eosinophils play
a central role. Initiation of effective treatment and treat-
ment guidance has relied mainly on repeated lung func-
tion measurements. We also need practical tools for
detection of asthmatic inflammation and to monitor its
course. This is especially important because there is
growing evidence that early pharmacologic intervention
can modify the course of asthma and even prevent the
development of asthma in patients with early manifesta-
tions of atopic disease.
The key feature affecting disease persistence is airway
remodeling (with changes in airway smooth muscle) as a
result of poorly controlled inflammation.1 Delay of anti-
inflammatory treatment is associated with lung function
loss over time,2 even though in the majority of patients the
risk for clinically significant lung function decline seems to
be relatively small.
HOW EARLY IS EARLY?
The benefits of acting early are well-illustrated by a
comparison of the effect of nebulized budesonide versus
symptomatic treatment with bronchodilators in infants
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(mean age 2.3 months) hospitalized with severe respira-
tory syncytial virus (RSV) bronchiolitis.3 By the time the
infants were 2–3 years of age, the incidence of asthma
among those babies who had received the inhaled corti-
costeroid was approximately 50% lower than those who
received only conventional symptomatic treatment
(Fig. 1). However, the study was an open one and the
result should be confirmed in a carefully controlled trial.
Early intervention with antihistamines has also been
shown to reduce the incidence of asthma in a selected
group of children with atopic dermatitis syndrome. In the
Early Treatment of Atopic Child (ETAC) study, the inci-
dence of asthma in grass- and mite-sensitized 1–2-year-
old children with atopic dermatitis was reduced by
approximately half following 18 months treatment with
cetirizine compared with placebo.4 The study was con-
tinued with an 18 month follow up and the effect of
cetirizine was sustained for the grass pollen-sensitized
infants over the full 36 months.5 The clinical relevance of
this study can be questioned because only a few children
of this age are grass pollen or mite sensitized. However,
there are at least two earlier studies that indicate the
same: antihistamine treatment may reduce asthma risk in
atopic children. Iikura et al.6 treated infants with atopic
dermatitis with either the antihistamine ketotifen or placebo
for 1 year. Asthma was observed in 13% of infants in the
ketotifen group and in 42% of infants in the placebo
group. In a study over 3 years with the antihistamine
ketotifen in children with elevated total IgE and a family
history of atopy, treatment reduced the incidence of
asthma compared with placebo (35 vs 9%, respectively).7
As an alternative approach, the Preventive Allergy
Treatment (PAT) study shows that it is possible to modulate
the immune system if treatment is started early enough. In
the PAT study of children aged 5–13 years with seasonal
allergic rhinoconjunctivitis, the incidence of asthma after
5 years was reduced from 56% in control subjects receiv-
ing conventional drug therapy to 23% in children receiv-
ing specific immunotherapy.8 The result should be
appreciated even though the study was not placebo con-
trolled. These kind of long-term interventions and follow
ups are difficult to perform in a fully controlled manner.
EOSINOPHILIC INFLAMMATION: UNMASKING
AN IMPORTANT TARGET GROUP
It seems that an important opportunity to prevent asthma
is often overlooked in patients who show some of the
signs of the disease (e.g. prolonged cough) but record
normal or near normal lung function. As a result, they
receive little, or inappropriate, treatment. We hypothe-
sized that many of these patients would show eosinophilic
inflammation, which is a characteristic marker of the
airway pathology usually encountered in asthma. This
could then be used to identify patients for appropriate
treatment with anti-inflammatory medication (e.g.
inhaled steroids or antileukotrienes).
To test the hypothesis, we investigated a population of
82 consecutive patients presenting to their general prac-
titioners with prolonged cough (more than 2 months) but
not other signs of asthma or any other pulmonary
disease, gastroesophageal reflux or rhinosinusitis.9 Ap-
proximately one-fifth of these patients showed sputum
eosinophilia. When tested for lung function, 36% of
patients with sputum eosinophilia were revealed as asth-
matics, yet the majority (64%) did not fulfill the functional
criteria for asthma. Further analysis of inflammatory
markers in another similar study population showed that
patients with eosinophilia, but relatively normal lung
function, form an intermediate group between real asth-
matics and healthy individuals.10
The literature suggests that patients with cough and
eosinophilia, but normal lung function, are relatively
rare.11,12 However, our experience indicates that they are
not rare and could be, in fact, more common than
patients with asthma. There is evidence that the condition
is an important and rather usual cause of prolonged
cough.13 It seems that both children and adults can have
episodes of eosinophilic inflammation during respiratory
infections or allergen exposure while having, most of the
Fig. 1 Infants (mean age 2.6 months; range 0–9 months)
receiving nebulized budesonide to treat obstruction associated
with respiratory syncytial virus bronchiolitis had a lower risk of
developing asthma at 2–3 years of age than infants who
received conventional symptomatic treatment. (), sympto-
matic treatment; (), budesonide 500 µg × 3, 7 days; ( ),
500 µg × 2, 2 months. Redrawn from Kajosaari et al.3
time, normal or close to normal lung function. Because
epidemiologic data on sputum eosinophilia in general
populations has been lacking, we made a survey in
Finland and Russia.
EOSINOPHILIC INFLAMMATION: COMMON IN
THE GENERAL POPULATION
We assessed the occurrence of sputum eosinophilia in
two geographically adjacent areas: North Karelia,
Finland, and in Pitkäranta, Russia. Seven hundred and
ninety Finns and 387 Russians, aged 25–54 years, were
randomly selected from the population registers. Patients
with known asthma were excluded from the study. The
prevalence of sputum eosinophilia was 22% among the
Finns and 19% among the Russians (T Petäys, pers.
comm.). Current smoking was significantly associated
with sputum eosinophilia and atopy was another risk
factor. The association of sputum eosinophilia and
bronchial hyperreactivity was not straightforward. There
were many individuals in the general population who
showed eosinophilia but not bronchial hyperreactivity.
The study indicated that sputum eosinophilia is common
in general populations and is partly associated with
cough and wheezing.
INTERVENE EARLY IN AIRWAY EOSINOPHILIA
Airway eosinophilia predisoposes a patient to asthma.
For example, in a study of 147 patients with prolonged
cough, the consequence of a delayed diagnosis of
asthmatic inflammation was that, after 1 year, 46 (31%)
had developed asthma.14 Indeed, in that study the pres-
ence of eosinophilia in blood, sputum or nasal secretion
in the first place represented a highly significant, approx-
imately fourfold, increase in the risk of developing
asthma. Similarly, of 33 children with symptoms suggest-
ing asthma but normal lung function, one-third went on
to develop the disease in 2 years.15 The data are still
scanty, but there seems to be an increased risk of asthma
in patients who have symptoms of disease, especially
prolonged cough and eosinophilia.
The benefit of early intervention in patients who show
some signs of asthma but have relatively normal lung
function was demonstrated in a study of adult patients
with prolonged cough and, in many cases, also eosino-
philic airway inflammation.10 Patients were randomized to
receive either inhaled beclomethasone dipropionate
or placebo for 3 months and were followed up for 1 year.
Symptom score was markedly reduced at both 3 months
and at 1 year compared with placebo (Fig. 2), as was the
level of the inflammatory marker eosinophil peroxidase
(EPO) in induced sputum.
The considerable delay in diagnosing asthma has
been acknowledged.16 In Helsinki, the mean delay from
start of symptoms suggesting asthma to the actual diag-
nosis of asthma is 1 year 7 months in children and
5 years 4 months in adults.17 This is mainly because the
inflammatory component of asthma is not detected in
symptomatic patients who still have, for most of the time,
normal or near normal lung function.
INTERVENE EARLY IN ASTHMA
Adults
The effects of early intervention have not been studied
extensively. A directly relevant study compared prospec-
tively two treatment strategies: (i) whether patients should
be treated with inhaled steroid from the beginning; or (ii)
whether treatment should be initiated with β2-adrenergic
receptor agonists alone.18 Patients with asthmatic
symptoms for less than 1 year and no previous anti-
inflammatory therapy inhaled either budesonide 1200 µg
or terbutaline 750 µg daily as the first and only regular
medication. Two years treatment with inhaled budesonide
resulted in almost complete clinical recovery and normal-
ization of lung function and was superior compared
with treatment with β2-adrenergic receptor agonists.
Bronchial biopsies were taken from a subgroup of
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Fig. 2 Treatment with inhaled beclomethasone dipropionate
(BDP) markedly reduced symptom score in patients with
prolonged cough and eosinophilic inflammation, but not ful-
filling the functional criteria for asthma, compared with
placebo. (), treatment for 3 months; (), treatment for 1 year.
Redrawn from Rytilä et al.10
patients and, after 3 months, budesonide-treated sub-
jects had a significantly greater fall in the number of
inflammatory cells than terbutaline-treated patients.19
The study was continued for a 3rd year to investigate
the effects of dose reduction or discontinuation of steroid
treatment. A delayed introduction of inhaled steroid was
also examined. The peak expiratory flow (PEF) level was
well maintained for the 3rd year in patients in whom the
daily budesonide dose was reduced from 1200 µg (by
Nebuhaler; Astrazeneca, Sweden) to 400 µg (by Turbu-
haler; Astrazeneca, Sweden). Most patients who switched
from budesonide to placebo showed a gradual and slight
decline in lung function, which became significant towards
the end of the 3rd year, but some patients did not deteri-
orate at all.2 The patients who were first treated with the
β2-adrenergic receptor agonist terbutaline for 2 years,
and were only subsequently treated with budesonide, did
not reach the same level of lung function within the 3rd
year as those who were treated with budesonide from the
beginning of the study (Fig. 3). Some functional revers-
ibility was lost by delaying the start of steroid treatment.
Adult patients with persistent asthma or chronic
obstructive pulmonary disease (COPD; baseline forced
expiratory volume in 1 s (FEV1) approximately 60% of
predicted), half of them having already used inhaled
steroids, had a 2.5 year intervention with bronchodilators
alone or with a β2-adrenergic receptor agonist (terbu-
taline) and steroid (beclomethasone).20 The addition of
inhaled steroid, but not an inhaled anticholinergic agent,
to maintenance treatment with the β2-adrenergic receptor
agonist was very beneficial in terms of symptoms and
bronchial responsiveness. The study was continued for
6 months after the first 2.5 years to investigate the effects
of adding beclomethasone 800 µg daily to those patients
who had not previously received it.21 Airway hyperrespon-
siveness showed no significant change after 6 months
during the new intervention, whereas it had shown a 
significant improvement at 3 months in patients who
started beclomethasone in the first phase. It seemed that
institution of inhaled steroid should not be postponed in
asthmatics with documented airway obstruction. Although
the investigation can hardly be considered an early inter-
vention study (the patients had a disease of moderate
severity and a long history of symptoms), it is important by
showing the risks of delaying anti-inflammatory treatment.
Osterman et al.22 studied adult asthmatics who had
their asthma diagnosis established not more than 1 year
before the study. However, most of them had a persistent,
albeit a rather mild, disease with symptoms for years. The
patients inhaled 400 µg budesonide daily (by Turbuhaler)
for 1 year and showed marked improvement in lung 
function and bronchial responsiveness compared with
placebo treatment.
Selroos et al.23 examined retrospectively the influence
of the duration of pretreatment symptoms on the response
to inhaled steroid treatment in steroid-naïve adult patients
with asthma. The duration of symptoms ranged from less
than 6 months to more than 10 years. Most of the 105
patients were treated with budesonide 800 µg daily for
1 year. During the 2nd year, the dose was reduced when
this was possible without a worsening of asthma control.
The maximum effects were seen usually after 1 years
treatment, with maintained control during the second
year. A significant negative correlation was found between
duration of symptoms and maximum increases in PEF
and FEV1 values. The results gave evidence that early
treatment of asthma with inhaled steroid may prevent
patients from developing chronic airway obstruction.
In a recent study, Selroos et al.24 evaluated how goals
had been achieved depending on when treatment with
inhaled steroids in asthma had been started. In 1988–1991,
treatment with budesonide was started in 462 patients
(mean age 37 years) and they were followed for 3.5 years.
Sixty-two percent of patients had had symptoms of asthma
for less than 2 years and the remaining patients had had
symptoms for 2–38 years. Early start of inhaled steroid
resulted in better lung function (78 vs 41% of patients had
FEV1 > 90% predicted) and exercise tolerance compared
with late start. Early treatment also decreased exacerba-
tions and the need for rescue medication.
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Fig. 3 Improvements in morning peak expiratory flow (PEF)
values in patients with newly detected asthma who either
received inhaled budesonide as first-line therapy immediately
after the diagnosis () or who received budesonide 2 years
after diagnosis (). Redrawn from Haahtela et al.2
Children
The Dutch childhood study25 included children with
chronic obstruction and moderate to severe asthma. The
aim was, in fact, not to investigate early intervention but
whether long-term treatment with a regular β2-adrenergic
receptor agonist plus inhaled steroid was more effective
than treatment with a β2-adrenergic receptor agonist
alone. The results were quite conclusive: the steroid-
treated group managed better in every respect. However,
full remission was achieved only by 60% of children,
which indicated that, in many of these children, some of
the functional reversibility was already lost when steroid
treatment was initiated.
Agertoft and Pedersen26 measured lung function and
growth in 278 children with mild to moderate asthma
during long-term treatment with inhaled budesonide and
compared openly the findings with those obtained from
children not treated with steroids. The children were ‘old’
asthmatics (mean duration of asthma 31/2 years) having
used β2-adrenergic receptor agonists and only occasion-
ally steroids. The difference in FEV1 and in many other
outcome variables between the two groups was very 
significant in favor of the budesonide-treated children.
Interestingly, the annual increase in FEV1 was greatest in
those children whose asthma was of shortest duration
when inhaled budesonide was started. Early intervention
with inhaled steroid seemed to prevent the development
of irreversible airway obstruction and reduce the risk of
undertreatment.
Konig and Shaffer27 observed, during an 8.4 year
follow up of children from the age of 6.5 years, that treat-
ment with cromolyn sodium or inhaled steroid, but not
as-needed bronchodilators alone, improved the long-
term prognosis. However, the prognosis of mild child-
hood asthma is favorable even without any treatment.
Oswald et al.28 followed 286 children for 28 years and
concluded that airway obstruction in mid-adult life was
present mainly in those with moderately severe asthma.
Subjects with relatively mild asthma who had not taken
inhaled steroids did not appear to be disadvantaged with
respect to lung function.
In the real world, compliance with inhaled cortico-
steroids declines with time. Most patients tend to take
their medication intermittently or periodically. The prelim-
inary findings of the Helsinki Early Intervention Childhood
Asthma (HEICA) study show that continuous and periodic
treatment with inhaled budesonide reduced exacerba-
tions in an almost similar manner following equivalent
6 month induction periods to remission.29 The result
shows that, provided we treat children early and effec-
tively in the first place, a periodic approach (2 week
courses of budesonide, as needed) may be just as effec-
tive as continuous therapy in the majority of children and
is likely to be what happens in real life.
WE NEED REASSUREMENT: THE START STUDY
The START (inhaled Steroid Treatment As Regular Therapy
in early asthma) study was planned to evaluate the bene-
fits of early intervention with inhaled steroids in patients
with mild, persistent asthma in the ‘real world’.30 Patients
were randomized to once-daily treatment with budes-
onide 200 µg (for patients < 11 years) or 400 µg (for
patients > 11 years) or placebo for 3 years. The double-
blind treatment was followed by a 2 year period of open
budesonide treatment. The primary outcome measures
were the time to the first severe exacerbation during the
first 3 years and the change in post-bronchodilator FEV1
during the entire 5 year study period. These measures
were chosen to reflect the progression of mild asthma
towards more severe disease and the extent of irreversible
airflow limitation, which reflects airway remodeling. The
first results will be ready this year and will certainly have
an major impact in the treatment strategies.
INHALED STEROIDS: DO THEY MODIFY THE
OUTCOME?
Long-term influence
One possibility to explore the long-term influence is 
to study what happens when treatment is stopped. The
studies of Haahtela et al.2,18 answered only partly the
questions how long should steroid treatment be continued
after remission, can the dose be reduced and what kind of
dosage schedules can be used? There are very few studies
addressing these issues in adults or in children.
Short-term studies on the withdrawal of inhaled steroid
therapy after treatment for periods of 4 weeks or less
suggest that bronchial responsiveness increases within
weeks of inhaled steroid reduction or withdrawal.31,32
However, patients in these studies have had persistent
asthma with a long symptom history. It has been shown
that considerably longer periods of treatment than 4 weeks
do not fully reverse the inflammatory changes in the
airways, even in patients with relatively mild asthma.33,34
Furthermore, van Den Toorn et al.35 observed recently
that atopic asthmatics in apparent clinical remission
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showed clearly increased numbers of inflammatory cells
in bronchial biopsies.
Juniper et al.36 showed that the improvements in
bronchial responsiveness induced by treatment with
budesonide for 1 year were maintained for at least 3
months after cessation or reduction of treatment with an
inhaled steroid. The result is remarkable, because the
patients did not have early asthma but, rather, a persistent
disease with at least moderate severity.
Van Schayck et al.37 withdrew inhaled bechlometha-
sone from a group of patients after 4 years treatment.
Before that, the patients were treated with bronchodila-
tors for the first 2 years and with beclomethasone for the
3rd and 4th years. Some patients with poor lung function
showed an accelerated rate of decline after withdrawal of
the inhaled steroid, but those with good lung function
showed no increase in the rate of decline of lung func-
tion. The investigators concluded that patients in the latter
group could stop inhaled steroid after treatment for
2 years. Again, the patients had persistent asthma with a
long history.
Osterman et al.22 followed their patients after the treat-
ment year for another 6 months without steroids. The
budesonide-treated patients maintained approximately
50% of their achieved improvement in bronchial respon-
siveness during the follow-up period, but only patients
with milder disease remained in the study, which some-
what invalidated the observations. Overall, the effects of
low-dose budesonide treatment for 1 year were mainly
temporary. Again, most of the patients did not have a
‘new’ disease.
Simons38 treated children with mild or moderate persis-
tent asthma with beclomethasone 400 µg daily for 1 year.
The beneficial effect on increased bronchial responsive-
ness disappeared in 2 weeks after cessation of treatment.
We need more information of the possible disease-
modifying effect. The problem is that the natural course
of asthma is not well established and is very difficult to
explore when all the patients are treated in one way or
another. There is no doubt that inhaled steroids reduce
mortality, hospital use, unscheduled visits to a physician
and to the emergency room, days missed from work or
school, use of rescue medication and the overall costs of
medical care.39,40 However, are inhaled steroids or any
other medication only suppressing the disease or are they
truly able to change the so-called natural course of the
disease (e.g. to prevent the decline in lung function in the
long term)? This is not known and it is going to be very
difficult to get any scientifically satisfactory answers.
HOW TO IMPROVE EARLY DIAGNOSTICS?
Eosinophils can be readily studied from induced
sputum.41,42 The presence of eosinophils in the sputum is
a more sensitive marker of asthmatic airway inflamma-
tion than blood eosinophils or increased serum eosino-
phil cationic protein (ECP).43,44 Soluble markers like ECP
and myeloperoxidase have been measured from the
sputum to assess the presence of eosinophils and neutro-
phils. Eosinophil cationic protein is often increased not
only in asthma, but also in COPD and bronchiectasis
and can be detected also in neutrophils.45 This reduces
the specificity of ECP to asthmatic inflammation. Myelo-
peroxidase is also detected in monocytes, which is a
minor confounding factor.
In addition, more cell-specific markers have been
introduced, such as eosinophil peroxidase (EPO)46 and
human neutrophilic lipocalin (HNL),47 which appear
clinically useful in the early detection of inflammatory
processes.10,48 Many other markers have been investi-
gated, but mainly as research tools. Induced sputum is
still not a method handy enough for quick diagnostics 
in clinical practice, even though it has been used in out-
patient care9 and sample processing has been simplified.49
Nitric oxide (NO) generation is increased in airway
inflammation and can be measured in exhaled air. The
measurement for the patient is simple and takes only
approximately 20 min. With the new equipment avail-
able, the result is reliable but may be confounded by NO
from the upper airways. Increased NO concentration is a
sign of mucosal inflammation, but not specific to asthma.
In clinical practice, however, it is not too difficult to rule
out other possible causes of an abnormal result by taking
a careful patient history. Thus, NO measurement seems
to be a good tool to screen asthmatic inflammation and
to monitor its course during treatment.50 New applica-
tions for clinical practice and even for home monitoring
are being developed. At the moment, the equipment is
expensive and the method can be used in major hospitals
only.
Recent application of using exhaled air for clinical
purposes has been studied with breath condensates. For
example, nitrosothiols (RS-NOs), which may limit the
detrimental effect of NO in the airways, are detectable in
breath condensate of healthy subjects and are increased
in patients with inflammatory airway diseases.51
In clinical work, the inflammatory component is increas-
ingly assessed to make the correct diagnosis and to
adjust the need of anti-inflammatory treatment, especially
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inhaled steroids. Is it helpful to grade the severity of
airway inflammation to identify those patients who are 
at risk of marked lung function decline? From clinical
experience we know that inflammation may be severe,
but lung function is not affected, or signs of inflammation
are lacking, but the patient’s bronchi are severely hyper-
reactive. Furthermore, patients in apparent clinical remis-
sion may show increased numbers of inflammatory cells
in their bronchial mucosa.35
The emerging new methods will cast light on the origin
of asthmatic inflammation as well as on the determinants
of disease persistence. Along with the development of
simple methods to assess airway inflammation, the
doctor gets a clearer picture of the disease. This means a
better understanding for the doctor and better tailored
treatment for the patient, which will further improve treat-
ment results.
CLINICAL REALITY AND FUTURE OPTIONS
When developing all the new methods, let us trust the
experienced adult clinician who states:
‘If asthma starts after a severe respiratory infection, is
nonatopic (intrinsic), is associated with severe eosino-
philic inflammation and marked bronchial hyperreactivity,
the prognosis is poor. The patient usually obtains a 
remission but needs regular treatment.’
However, there is increasing evidence that, in both chil-
dren and adults, early and effective therapy with inhaled
steroids results in long-term remission in the majority of
patients.2,26,29
The Finnish Asthma Programme39 recommends, in line
with many other guidelines, anti-inflammatory medica-
tion, preferably with inhaled steroids, as first-line treat-
ment to gain control of the disease as fast as possible.
Figure 4 illustrates the development of the use of inhaled
steroids (preventers) and short-acting β2-adrenergic
receptor agonists (relievers) in Finland. In 1994, the ratio
of preventers to those of relievers exceeded 1.0, indicat-
ing a profound change in treatment practices.
When treatment is started, the concept of induction
treatment can be used. Induction is followed by mainte-
nance treatment and treatment of relapses. Induction
with a high dose of inhaled steroid is justified according
to studies where markers of asthmatic inflammation have
been used as outcome measures.52,53 Tukiainen et al.
observed, in newly detected asthmatics, that decreases in
bronchial hyperreactivity and serum inflammation markers
were larger with 800 µg budesonide daily compared with
200 µg, even though the lung function outcome measure-
ments did not differ.53
The future also holds other promises. Exploration of the
role of various cytokines in the pathophysiology of asthma
has provided ideas for novel therapies. There are several
ways to inhibit the function of cytokines.54 The proinflam-
matory cytokines interleukin (IL)-4, IL-5, IL-13 and tumor
necrosis factor-α have been the first targets. The results of
preliminary clinical trials have been variable and partly
disappointing, which may also depend on the patients
included. Persistent asthma is difficult to reverse, but early
stages of asthma could be more responsive to these kind
of approaches. The new monoclonal anti-IgE is helping
even severe allergic asthmatics,55,56 but could help best
patients with newly detected asthma associated with other
atopic manifestations, such as rhinitis and dermatitis.
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